コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ongation factor alpha1) and eEF2 (eukaryotic elongation factor 2).
2 sleep-related gene encoding the translation elongation factor 2.
3 protein synthesis caused by inactivation of elongation factor 2.
4 ptide is identical to residues 581 to 589 of elongation factor 2.
5 nslocates to the cytosol and ADP-ribosylates elongation factor 2.
6 ocates into the cytosol where it inactivates elongation factor 2.
7 ot(ID)-predicted PPI-hot spots of eukaryotic elongation factor 2.
8 synthesis by ADP-ribosylation of eukaryotic elongation factor 2.
9 ible for the trimethylation of lysine 509 on elongation factor 2.
10 re toxin to reach the cytosol and inactivate elongation factor 2.
11 bosyltransferase activity against eukaryotic elongation factor 2.
12 found in archaeal and eukaryotic translation elongation factor 2.
13 single amino acid substitution in eukaryotic elongation factor 2.
14 inhibition at the fungal protein eukaryotic elongation factor 2.
15 NAD-dependent ADP-ribosylation of eukaryotic elongation factor 2.
16 ding of the C domain of DT to its substrate, elongation factor-2.
17 cells via ADP-ribosylation of the eukaryotic elongation factor-2.
18 inase in turn phosphorylates and inactivates elongation factor-2, a key mediator of ribosomal transfe
19 tresses on the phosphorylation of eukaryotic elongation factor 2 also differed: oxidative stress elic
20 reduced phosphorylation levels of eukaryotic elongation factor 2 and also requires the presence of el
21 ed diphtheria toxin (DT), which binds to the elongation factor 2 and blocks protein synthesis, can sp
22 ation but increases the association of human elongation factor 2 and human heterogeneous nuclear ribo
23 catalyzed the ADP-ribosylation of eukaryotic elongation factor 2 and inhibited protein synthesis.
26 the presence of the translocase, eukaryotic elongation factor 2, and guanosine 5'-triphosphate hydro
27 tes and inactivates eukaryotic translational elongation factor-2, and thus can modulate the rate of p
28 osomal protein S4, malate dehydrogenase, and elongation factor 2, as well as two novel parasite prote
29 tep in the posttranslational modification of elongation factor-2 at His(715) that yields diphthamide,
30 4 resulted in increased dephosphorylation of elongation factor 2, but had no effect on phosphorylatio
31 kills by ADP-ribosylation of the translation elongation factor 2, but many of the host factors requir
33 (P < 0.05) and phosphorylation of eukaryotic elongation factor 2 decreased (P < 0.05) after exercise
34 esent on archaeal and eukaryotic translation elongation factor 2, diphthamide represents one of the m
35 regions of endogenous eukaryotic translation elongation factor 2 (eEF-2) gene] using the Clustered Re
36 y increase the phosphorylation of eukaryotic elongation factor 2 (eEF-2) in extracts of NIH3T3 cells.
37 demonstrated that the activity of eukaryotic elongation factor 2 (eEF-2) kinase was markedly increase
38 ibosome association of the GTPase eukaryotic elongation factor 2 (eEF-2) resulting from its specific
39 by phosphorylating its substrate, eukaryotic elongation factor 2 (eEF-2), thereby reducing its affini
43 ulin-dependent phosphorylation of eukaryotic elongation factor-2 (eEF-2) by eukaryotic elongation fac
44 d autophagy, whereas silencing of eukaryotic elongation factor-2 (eEF-2) kinase, a protein synthesis
45 induced the phosphorylation of a eukaryotic elongation factor-2 (eEF-2) kinase, radiation sensitivit
46 eased level of phosphorylation of eukaryotic elongation factor-2 (eEF-2) was observed in the brains a
47 at phosphorylates and inactivates eukaryotic elongation factor 2 (eEF2 kinase; eEF2K) is subject to m
48 in 1 (4EBP1 Thr37/46; 14 +/- 3%), eukaryotic elongation factor 2 (eEF2 Thr56; -47 +/- 4%), extracellu
50 ture cortical neurons express the eukaryotic elongation factor 2 (eEF2) at lower levels than other ce
53 osphatase calcineurin and promote eukaryotic elongation factor 2 (eEF2) dephosphorylation, increasing
55 an target of rapamycin (mTOR) and eukaryotic elongation factor 2 (eEF2) in the mPFC, effects recently
58 diphthamide on human eukaryotic translation elongation factor 2 (eEF2) is the target of ADP ribosyla
59 kade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII),
60 mammalian starvation response is eukaryotic elongation factor 2 (eEF2) kinase (eEF2K), which suppres
61 roteasome-targeted degradation of eukaryotic elongation factor 2 (eEF2) kinase and activation of the
62 MDA receptors at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase, resulting in reduced
63 an inhibitory phosphorylation of eukaryotic elongation factor 2 (eEF2) kinase, which in turn promote
66 elongation is phosphorylation of eukaryotic elongation factor 2 (eEF2) on threonine 56 (T56) by eEF2
68 on inhibition through eukaryotic translation elongation factor 2 (eEF2) phosphorylation, which in tur
70 mpairs the ability of eukaryotic translation elongation factor 2 (eEF2) to bind to the ribosome via T
71 through inhibition of eukaryotic translation elongation factor 2 (eEF2) via adenosine diphosphate (AD
72 ssociated hyperphosphorylation of eukaryotic elongation factor 2 (eEF2) was blunted with selective AM
73 ing protein (Tbp) and eukaryotic translation elongation factor 2 (Eef2) were not affected by inflamma
75 increasing the phosphorylation of eukaryotic elongation factor 2 (eEF2), a key component of the trans
76 ne residue unique for eukaryotic translation elongation factor 2 (eEF2), a key ribosomal protein.
78 also increased phosphorylation of eukaryotic elongation factor 2 (eEF2), a process known to inhibit p
79 and found that phosphorylation of eukaryotic elongation factor 2 (eEF2), a ribosomal translocase whos
80 In the periphery, OXT activates eukaryotic elongation factor 2 (eEF2), an essential mediator of pro
81 ion (inactivation) of eukaryotic translation elongation factor 2 (eEF2), an important molecule for pr
82 6k), ribosomal protein S6 (rpS6), eukaryotic elongation factor 2 (eEF2), and eukaryotic initiation fa
83 es the involvement of eukaryotic translation elongation factor 2 (eEF2), the phosphorylation of which
84 f the diphthamide modification on eukaryotic elongation factor 2 (eEF2), we generated an eEF2 Gly(717
85 In eukaryotes translocation is ensured by elongation factor 2 (eEF2), which catalyses the process
86 n this study, we demonstrate that eukaryotic elongation factor 2 (eEF2), which catalyzes the GTP-depe
87 controlled by phosphorylation of eukaryotic elongation factor 2 (eEF2), which inhibits its activity
88 ar target has been identified as translation elongation factor 2 (eEF2), which is responsible for the
89 lation of mRNA translation factor eukaryotic elongation factor 2 (eEF2), which results in inhibition
90 a simultaneous inhibition of the eukaryotic elongation factor 2 (eEF2), which results in tumor suppr
96 receptor-dependent suppression of eukaryotic elongation factor-2 (eEF2) phosphorylation thus reversin
102 the endothelium, promotes phosphorylation of elongation factor-2 (EF-2) and prostacyclin production,
104 DT transfers the ADP-ribose group of NAD to elongation factor-2 (EF-2), rendering EF-2 inactive.
105 (4) genes responsible for protein synthesis (elongation factor-2 [EF-2], eukaryotic initiation factor
106 osttranslational modification on translation elongation factor 2 (EF2) in archaea and eukaryotes.
109 ), beta actin (ACTB), eukaryotic translation elongation factor 2 (EF2), glyceraldehyde-3-phosphate de
110 hibitor Exotoxin A (ToxA), which ribosylates elongation factor 2 (EF2), upregulates a significant sub
111 de, a modification found only on translation elongation factor 2 (EF2), was proposed to suppress -1 f
115 2 is unable to ADP ribosylate and inactivate elongation factor-2 (EF2), owing to a low level of DPH4
117 thetase, glutaminyl-transfer RNA synthetase, elongation factor 2, elongation factor 1delta, and eukar
119 ng vimentin, EH-domain-containing protein 2, elongation factor 2, glucose-regulated protein 78, trans
120 ene product, ribosomal protein S6, cyclin K, elongation factor-2, Grb2-associated protein 2, and othe
122 m nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, inhibiting prot
123 abamiquine, a Plasmodium-specific eukaryotic elongation factor 2 inhibitor, to select for resistant P
129 almodulin-activated alpha-kinase, eukaryotic elongation factor 2 kinase (eEF-2K), serves as a master
132 plitudes by reducing postsynaptic eukaryotic elongation factor 2 kinase (eEF2K) activity subsequent t
143 protein synthesis by inactivating eukaryotic elongation factor 2 kinase (eEF2K), which, when active,
148 d higher levels of phosphorylated eukaryotic elongation factor 2 kinase than were observed in Mtm1 p.
149 des the activation of eukaryotic translation elongation factor 2 kinase with a consequent inhibition
150 ering RNA (siRNA) to eEF2 kinase (eukaryotic elongation factor 2 kinase) blocked the dendritic MAP1B
151 ivation and downregulation of the eukaryotic elongation factor 2 kinase, which normally inhibits tran
153 , rat, and Caenorhabditis elegans eukaryotic elongation factor-2 kinase (eEF-2 kinase) and found that
155 gy by 2-DG was associated with activation of elongation factor-2 kinase (eEF-2 kinase), a structurall
160 inase inhibitors against a mammalian enzyme, elongation factor-2 kinase (eEF-2K), and the effect of t
162 ic elongation factor-2 (eEF-2) by eukaryotic elongation factor-2 kinase (EF2K), which inhibits elonga
164 -2 kinase and a putative nematode eukaryotic elongation factor-2 kinase also encode the catalytic dom
165 gments of homology present in rat eukaryotic elongation factor-2 kinase and a putative nematode eukar
166 d neurotrophic factor expression, eukaryotic elongation factor-2 kinase function, and increased surfa
170 ot inhibit the phosphorylation of eukaryotic elongation factor 2 or augment subsequent expression of
171 chanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DD
172 city through ADP-ribosylation of translation elongation factor 2, predicated on binding to specific c
174 P dissociation inhibitor beta, ATP synthase, elongation factor 2, protein disulfide isomerase, nucleo
176 modification of histidine 715 in eukaryotic elongation factor 2, resulted in tagraxofusp resistance.
178 RNA reporter constructs with the 5'-TOP from elongation factor 2 showed decreased translational activ
179 cytosolic ribosomes, as well as translation elongation factors; (2) slows down translation elongatio
180 osttranslational modification of translation elongation factor 2 that is conserved in all eukaryotes
181 d to interfere with binding of the substrate elongation factor 2 to the enzymatic active site of the
182 itor that impairs the function of eukaryotic elongation factor 2, whereas the rpl40a and rpl40b null